Pretreatment Serum Testosterone and Androgen Deprivation: Effect on Disease Recurrence and Overall Survival in Prostate Cancer Patients Treated With Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1143-1149

  Taira, Al V ^a   Merrick, Gregory S ^b   Galbreath, Robert W ^b   Butler, Wayne M ^b   Wallner, Kent E ^c   Allen, Zachariah A ^b   Lief, Jonathan H ^b   Adamovich, Edward ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Prostate cancer; Survival; Testosterone

Indexed keywords

ANDROGEN DEPRIVATION; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CAUSE-SPECIFIC SURVIVAL; OVERALL SURVIVAL; PRE-TREATMENT; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; PROSTATE CANCERS; SERUM TESTOSTERONE; SURVIVAL; TESTOSTERONE;

PATIENT MONITORING;

BODY FLUIDS;

ANDROGEN; ANTIANDROGEN; GONADORELIN AGONIST; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; REFERENCE VALUES; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 67649553273     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.046     Document Type: Article

References (33)

1. Matsumoto A.M. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57 (2002) M76-M99
2. Miner M.M., and Sadovsky R. Evolving issues in male hypogonadism: Evaluation, management, and related comorbidities. Cleve Clin J Med 74 Suppl 3 (2007) S38-S46
3. Ding E.L., Song Y., Malik V.S., et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. J Am Med Assoc 295 (2006) 1288-1299
4. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116 (2007) 2694-2701
5. Laughlin G.A., Barrett-Connor E., and Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93 (2008) 68-75
6. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
7. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
8. San Francisco I.F., Regan M.M., Dewolf W.C., et al. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341-1345 discussion 1345-1346
9. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
10. Zhang P.L., Rosen S., Veeramachaneni R., et al. Association between prostate cancer and serum testosterone levels. Prostate 53 (2002) 179-182
11. Imamoto T., Suzuki H., Fukasawa S., et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47 (2005) 308-312
12. Isom-Batz G., Bianco Jr. F.J., Kattan M.W., et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173 (2005) 1935-1937
13. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
14. Teloken C., Da Ros C.T., Caraver F., et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
15. Yamamoto S., Yonese J., Kawakami S., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 52 (2007) 696-701
16. Zagars G.K., Pollack A., and von Eschenbach A.C. Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49 (1997) 327-334
17. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol 6 (2000) 78-84
18. Partin A.W., Mangold L.A., Lemm D.M., et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
19. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
20. Huggins C., Stevens R., and Hodges C. Studies on prostatic cancer II: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg (1941) 209-223
21. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
22. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. J Am Med Assoc 292 (2004) 821-827
23. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
24. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs. radiation alone for prostate cancer: A randomized trial. J Am Med Assoc 299 (2008) 289-295
25. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
26. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
27. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
28. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
29. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
30. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
31. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
32. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 669-677
33. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305